Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to sign a written consent form agreeing to take part in the trial
• People who are 15 years of age or older at the time of signing the consent form
• People who have been diagnosed with metastatic adrenocortical carcinoma (ACC) that has spread to the liver and is causing symptoms, confirmed through a tissue or cell sample test
• People with a physical functioning level that meets the trial's requirements — for those under 16, a Lansky score of 50% or higher; for those 16 and over, a Karnofsky score of 50% or higher (confirm with trial site)
• People whose cancer can be measured on scans using standard criteria (RECIST v1.1)
• People who have evidence on scans that the cancer has spread to areas outside the liver as well
• People who are willing to allow stored tissue samples to be used for research purposes, if available
• People whose blood test results show that their bone marrow, kidneys, liver, and blood clotting are all functioning at an adequate level (blood tests must be done within 28 days before starting treatment)
• People who are female and of childbearing potential must have a negative pregnancy test within 72 hours before starting treatment
• People who are female and of childbearing potential must be willing to use two methods of birth control, be surgically sterile, or abstain from heterosexual activity during the study and for 120 days after the last dose of study medication
• People who are male must agree to use an adequate method of contraception from the first dose of study treatment through 120 days after the last dose

Who may not be able to join:

• People who are currently taking part in, or have taken part in, another clinical trial involving an experimental treatment or device within the 4 weeks before the study start date
• People who have previously had radiation therapy to the same area of the body being treated in this trial, in a way that would cause the radiation fields to overlap (including a treatment called Y90)
• People who have a condition that weakens the immune system, or who have been taking steroid or immune-suppressing medications within 7 days before the study start date (low-dose steroids taken for adrenal or pituitary conditions are an exception)
• People who have received a certain type of immune-targeting medication called a monoclonal antibody within 4 weeks before the study start date, or who have not yet recovered from side effects of such a treatment (non-immune-related monoclonal antibodies such as those used for eczema, hives, or asthma are an exception)
• People who have had chemotherapy or targeted drug therapy within 2 weeks before the study start date, or who have not yet recovered from side effects of a previous treatment (mild nerve-related side effects or hair loss at Grade 2 or below may be an exception — confirm with trial site)
• People who have had major surgery and have not yet adequately recovered from it before starting the study treatment
• People who have another cancer that is currently growing or requires active treatment (skin cancers such as basal cell or squamous cell carcinoma, or early-stage cervical cancer that has been treated, may be exceptions)
• People who have active cancer spread to the brain or the membranes surrounding the brain and spinal cord; people with previously treated brain metastases that are now stable may be considered, provided certain conditions are met (confirm with trial site)
• People who have an active autoimmune disease that required treatment within the past 3 months, or a history of a severe autoimmune condition (some milder or well-controlled conditions such as vitiligo, treated childhood asthma, stable hypothyroidism, or Sjögren's syndrome may be exceptions — confirm with trial site)
• People who have a current or past lung condition called interstitial lung disease or pneumonitis (non-infectious) that required steroid treatment, or who currently have pneumonitis
• People who have an active infection that requires treatment with medication
• People whose medical history, current condition, or test results could interfere with the trial results or their ability to complete the trial, as judged by the treating doctor
• People with known psychiatric conditions or substance use disorders that would make it difficult to follow the trial requirements
• People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the trial period and for 120 days after the last dose of treatment
• People who have previously been treated with certain immune checkpoint or T-cell targeting therapies, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibodies (such as ipilimumab)
• People with a known history of HIV infection
• People with known active Hepatitis B or Hepatitis C infection
• People who have received a live or live-attenuated vaccine within 30 days before the study start date (vaccines that do not contain live virus are permitted)

Important: Always verify eligibility with the trial site directly before applying.